

Journal of Visualized Experiments

Assessing Stem Cell DNA Integrity for Cardiac Cell Therapy

--Manuscript Draft--

Article Type:	Invited Methods Article - JoVE Produced Video
Manuscript Number:	JoVE58971R2
Full Title:	Assessing Stem Cell DNA Integrity for Cardiac Cell Therapy
Keywords:	DNA integrity; DNA damage; iPS cells; comet assay; γ H2A.X; DNA damage response; iPS-cardiomyocytes; cell transplantation; cardiac regeneration
Corresponding Author:	Ram Kannappan University of Alabama at Birmingham Birmingham, AL UNITED STATES
Corresponding Author's Institution:	University of Alabama at Birmingham
Corresponding Author E-Mail:	ramkn@uab.edu
Order of Authors:	Jessica Marie Miller Nikhil Maneesh Mardhekar Vasanthi Rajasekaran Jianyi Zhang Ramaswamy Kannappan
Additional Information:	
Question	Response
Please indicate whether this article will be Standard Access or Open Access.	Standard Access (US\$2,400)
Please indicate the city, state/province, and country where this article will be filmed . Please do not use abbreviations.	Birmingham, Alabama, USA

Ram Kannappan, Ph.D.
10/23/2018
205-996-0826

Dr. Lyndsay Tryoyer,
Science Editor,
Editorial Department
The Journal of Visualized Experiments,
Cambridge, MA.

Subject: **SUBMISSION OF REVISED ARTICLE FOR EVALUATION**

Dear Editor,

We are excited to submit our re-revised manuscript entitled “Assessing Stem Cell DNA Integrity for Cardiac Cell Therapy” to consider for publication in the Journal of Visualized Experiments. In this second revision, we have addressed all the issues raised by the Editor. Additionally, a point by point response to all the comments were provided as rebuttal.

We are looking forward for positive comments from the editor and reviewers.

Sincerely,

Ram Kannappan, Ph.D.
Assistant Professor
Department of Biomedical Engineering
University of Alabama at Birmingham

TITLE:**Assessing Stem Cell DNA Integrity for Cardiac Cell Therapy****AUTHORS AND AFFILIATIONS:**

Jessica M. Miller^{1*}, Nikhil Mardhekar^{1*}, Vasanthi Rajasekaran¹, Jianyi Zhang¹, Ramaswamy Kannappan¹

¹Department of Biomedical Engineering, School of Engineering, School of Medicine, The University of Alabama at Birmingham, Birmingham, AL, USA

*These authors contributed equally.

Corresponding Author:

Ramaswamy Kannappan (ramkn@uab.edu)
Tel: (205) 996-0826

Email Address of Co-authors:

Jessica M. Miller (jessie13@uab.edu)
Nikhil Mardhekar (pokemon3@uab.edu)
Vasanthi Rajasekaran (vraja22@uab.edu)
Jianyi Zhang (jayzhang@uab.edu)

KEYWORDS:

DNA integrity, DNA damage, iPS cells, comet assay, γ H2A.X, cardiomyocytes, cell transplantation

SUMMARY:

Here, we provide a detailed description of an experimental setup for an analysis of the assessment of DNA integrity in stem cells prior to cell transplantation.

ABSTRACT:

Stem and stem-cell-derived cells have immense potential as a regenerative therapy for various degenerative diseases. DNA is the storehouse of genetic data in all cells, including stem cells, and its integrity is fundamental to its regenerative ability. Stem cells undergo rapid propagation in labs to achieve the necessary numbers for transplantation. Accelerated cell growth leads to the loss of DNA integrity by accumulated metabolites, such as reactive oxygen, carbonyl, and alkylating agents. Transplanting these cells would result in poor engraftment and regeneration of the deteriorating organ. Moreover, transplanting DNA-damaged cells leads to mutations, DNA instability, cellular senescence, and possibly, life-threatening diseases such as cancer. Therefore, there is an immediate need for a quality control method to evaluate the cell's suitability for transplantation. Here, we provide step-by-step protocols for the assessment of the DNA integrity of stem cells prior to cell transplantation.

INTRODUCTION:

Experimental and clinical evidence demonstrates that cell transplantation can moderately improve the left ventricle contractile performance of failing hearts¹⁻⁹. Recent advances have

opened further appealing opportunities for cardiovascular regeneration; these include the forced expression of reprogramming factors in somatic cells to induce pluripotency and differentiate these induced pluripotent stem cells (iPSC) into different cardiac lineages, importantly cardiomyocyte (CM)¹⁰⁻¹³. The hereditary material in every cell, including the artificially generated iPSCs and iPSC-derived CM (iPS-CM), is DNA. The genetic instructions stored in DNA dictates the growth, development, and function of cells, tissues, organs, and organisms. DNA is not inert; cell metabolites, such as reactive oxygen, carbonyl, and nitrogen species, and alkylating agents can cause DNA damage *in vitro* and *in vivo*¹⁴⁻¹⁷. Importantly, DNA damage occurs intuitively in every cell, with a significant frequency. If these damages are not corrected, it will lead to DNA mutation, cellular senescence, the loss of DNA and cell integrity, and possibly, diseases, including life-threatening cancers. Therefore, retaining DNA integrity is essential to any cell, especially iPSCs, that has enormous potential in the clinic.

For assessing the quantity and integrity of isolated genomic DNA, expensive equipment is available on the market. However, there are no simple and cost-effective methods to assess the DNA integrity in cells without isolating the cells. Moreover, user-induced DNA degradation during DNA isolation is one of the major drawbacks in using these methods. The single-cell gel electrophoresis (known as comet assay)^{18,19} and γ H2A.X immunolabeling⁸ techniques are fundamental approaches in research labs for assessing DNA damage. These two methods do not require expensive equipment or isolated genomic DNA to analyze DNA integrity^{8,20,21}. Since, these techniques have been performed with whole cells; user-induced DNA/RNA/protein degradation during the sample preparation will not affect these protocols. Here, to assess the DNA damage and DNA damage response in stem and stem-cell-derived cells, we provide step-by-step protocols to perform both the comet assay and γ H2A.X immunolabeling. Moreover, combining these two approaches, we propose a naive assessment that can be used to evaluate the cell's suitability for transplantation.

The comet assay, or single-cell gel electrophoresis, measures the DNA breaks in cells. Cells embedded in low-melting agarose are lysed to form nucleoids containing supercoiled DNA. Upon electrophoresis, small pieces of fragmented DNA and broken DNA strands migrate through the agarose pores, whereas the intact DNA, due to their enormous size and their conjugation with the matrix protein, will have a restricted migration. The pattern of stained DNA under a fluorescence microscope mimics a comet. The comet head contains intact DNA and the tail is composed of fragments and broken DNA strands. The fraction of DNA damage can be measured by the fluorescence intensity of the damaged DNA (comet tail) relative to the intact DNA (comet head) intensity. The parameter tail moment can be calculated as shown in **Figure 1**.

DNA damage induces the phosphorylation of histone H2A.X (γ H2A.X) at Ser139 by ATM, ATR, and DNA-PK kinases. The phosphorylation and recruitment of H2A.X at DNA strand breaks is called DNA damage response (DDR) and happens rapidly after DNA is damaged. Following this process, checkpoint-mediated cell cycle arrest and DNA repair processes are initiated. After the successful completion of DNA repair, γ H2A.X is dephosphorylated and inactivated by phosphatases. Prolonged and multiple DNA strand breaks lead to the accumulation of γ H2A.X foci in DNA. This indicates the cell's inability to repair the DNA damage and the loss of DNA integrity. These γ H2A.X

foci in DNA can be identified by and the number of DDR foci can be counted using the protocol in section 2.

PROTOCOL:

1. Comet Assay

1.1. Reagent preparation

1.1.1. For low-melting-point agarose, place 500 mg of low-melting agarose in 100 mL of DNA-/RNA-free water. Heat the bottle in a microwave oven until the agarose dissolves. Place the bottle in a 37 °C water bath until needed.

NOTE: For further reading, see Azqueta *et al.*, who studied the effects of agarose concentration on the DNA-unwinding time and several electrophoresis factors²³.

1.1.2. Dilute SYBR green DNA dye in Tris-EDTA (TE) Buffer at a 1:10,000 ratio to obtain a 1x working stock dye solution. This dye is light-sensitive, so store it in a dark place.

1.1.3. For the cell lysis buffer, dissolve 100 mL of lysis buffer (2.5 M NaCl, 0.1 M EDTA, 10 mM Tris, 1% Triton X-100) in deionized water (DI H₂O). Then, add 10 M NaOH to adjust the pH to 10.0. Cool the buffer to 4 °C.

1.1.4. For the alkaline DNA-unwinding/electrophoresis running buffer, dissolve 1 L of alkaline solution (0.3 M NaOH, 1 mM EDTA) in DI H₂O. Cool the buffer to 4 °C. Make sure the pH >13.

1.1.5. For precoated comet slides, place a few drops of 0.5% agarose on a glass slide. Immediately, using the flat surface of another slide, spread the agarose to form a thin layer of agarose coating.

NOTE: Dry the slides before using.

1.1.6. For iPS cell culture, briefly culture iPS cells in basement-membrane-matrix-coated (see **Table of Materials**) culture plates in mTESR1 culture medium until confluency is reached.

NOTE: Human-cardiac-fibroblast-derived iPS cells were used in this protocol. The reprogramming of iPS cell derivation and culture conditions is described in recent articles from our research group^{12,13,21}.

1.2. Sample preparation

1.2.1. Discard the culture medium and wash the cells. Dissociate the cells using detachment solution (see **Table of Materials**). Wash the cell pellet with phosphate-buffered saline (PBS) and resuspend the cells in PBS at 1 x 10⁵ cells/mL.

1.3. Sample slide preparation

NOTE: Perform the following steps under low-light conditions to avoid ultraviolet-light-induced cell damage.

1.3.1. Mix 10 μL of cell suspension and 90 μL of agarose solution (1:10 ratio) in a tube. Place the tube in a 37 °C water bath to prevent the agarose from solidifying.

1.3.2. Mix the solutions without introducing air bubbles and pipette 70 μL /spot onto the precoated comet slide. Using a pipette tip, spread the cell agarose mixture to form a thin layer. Place the slide in 4 °C for 15 min.

1.3.3. In a container, completely submerge the slide in cold lysis buffer. Place the container in the dark at 4 °C for 1 h.

1.3.4. Replace the lysis buffer with cold alkaline solution. Make sure the slides are completely submerged. Place the container in the dark at 4 °C for 30 min.

1.4. Electrophoresis

1.4.1. Place the slide in a horizontal electrophoresis tank. Fill the tank with cold alkaline electrophoresis buffer until the slides are completely submerged. Apply voltage at 1 V/cm for 15 to 30 min.

NOTE: Total voltage = distance between the electrodes x 1 V

1.4.2. In a container, completely submerge the slide in cold DI H₂O. After 2 min, remove the DI H₂O and add fresh DI H₂O. Repeat this step.

1.4.3. Replace the DI H₂O with cold 70% ethanol. Wait 5 min. Gently remove the slide, do not tilt it, and let it air-dry.

1.4.4. Once dried, add 100 μL of diluted DNA dye to each spot. Wait 15 min at room temperature. Using a FITC filter in an epifluorescence microscope, take images of 50 to 100 comets in total per sample.

1.5. Image analysis and calculation of the results

1.5.1. For scoring the comets, use the National Institutes of Health's (NIH) ImageJ with comet assay plugin (download ImageJ here: <https://imagej.nih.gov/ij/download.html>; download the plugin here: <https://www.med.unc.edu/microscopy/resources/imagej-plugins-and-macros/comet-assay/>).

NOTE: The plugin comes with a PDF instruction which contains all details to perform the analysis. Additionally, screenshots of the comet analysis are shown in **Figure 2A-C**. Representative comet images of control and doxorubicin (Doxo)-treated iPS cells and the quantification of the comets are shown in **Figure 3A-C**.

2. DNA Damage Response

2.1. Sample and reagent preparation

2.1.1. For an iPS-CM cell culture, culture iPS-CM cells in basement-membrane-matrix-coated (see **Table of Materials**) culture plates in RPMI medium supplemented with B-27 (CMM) until confluency is reached.

NOTE: Human-iPS-cell-derived cardiomyocytes were used in this protocol. The protocol for iPS cell differentiation into cardiomyocytes can be found in recent articles from our research group^{12,13,21}.

2.1.2. Seed iPS-CMs in chamber slides.

2.1.2.1. Discard the culture medium from the iPS-CM wells. Wash the cells three times with PBS.

2.1.2.2. Add 1 mL of 0.25% trypsin per well and incubate at 37 °C for 5 min. Check the plate under a microscope for cell detachment. Add 1 mL of CMM to stop the trypsin.

2.1.2.3. Place cell suspension in a 15 mL tube and centrifuge for 5 min at 4 °C and 200 x *g*. Discard the medium, add 1 mL of CMM, and resuspend the cells. Count the cells and adjust the cell count to obtain 20×10^5 cells in 1.6 mL of CMM.

2.1.2.4. Seed 200 µL of cell suspension per well of the 8-well chamber slide (see **Table of Materials**). Tap the slide gently to spread the cells around the well and incubate at 37 °C.

2.1.3. For the iPS-CM doxorubicin treatment, discard the culture medium from the iPS-CM wells. Wash the cells with PBS. Treat the cells with 1 µM doxorubicin and CMM for 4 h. Aspirate the medium and wash the cells with PBS.

2.1.4. For the blocking buffer, prepare 10 mL of bovine serum albumin (BSA) solution containing 3% BSA and 0.05% Triton X-100. To prepare 10 mL of blocking buffer, add 1 mL of normal donkey serum to 9 mL of prepared BSA solution.

2.1.5. For the primary antibody solution, add 1 µL of anti-rabbit phospho-histone H2A.X (Ser139) antibody to 200 µL of blocking buffer.

2.1.6. For the secondary antibody mix, add 1 µL each of fluorochrome-conjugated anti-rabbit secondary antibody, DAPI, and fluorochrome-conjugated phalloidin to 200 µL of blocking buffer.

2.2. Immunolabeling

2.2.1. Wash the cells three times with PBS and add 200 μ L of freshly prepared 4% paraformaldehyde (PFA) to each well. Fix the cells for 20 min in the dark at room temperature. Wash the cells with PBS.

2.2.2. Remove the PBS and add 200 μ L of blocking buffer per well and block for 30 min in a humidified chamber at room temperature. Remove the blocking buffer and add 200 μ L of primary antibody solution. Incubate for 45 min in a dark, humidified chamber at room temperature. Then, wash the wells three times with PBS.

2.2.3. Remove the PBS and add 200 μ L of secondary antibody mix. Incubate for 45 min in a dark, humidified chamber at room temperature. Then, wash the wells three times with PBS. Wash with DI H₂O before mounting them with antifade. Place a coverglass and store the slides in the dark at 4 °C.

2.2.4. Using an epifluorescence microscope, take three to five images of random fields per sample, as shown in **Figure 4A**, and proceed to image analysis.

2.3. Counting of the DDR foci

2.3.1. Download and install CellProfiler²⁴ (<http://cellprofiler.org>).

2.3.2. NOTE: Image processing in this study was performed using CellProfiler version 2.1.1. Tutorials for CellProfiler that were used can be found elsewhere (<https://www.youtube.com/watch?v=PvhRL9xpduk&list=PL7CC87670239B4D10>). If a newer version of CellProfiler is being used, the pipeline might require minor adaptations.

2.3.3. Download the pipeline **punctae_gH2AX.cpipe**. Select **File > Import > Pipeline** from the file and choose **punctae_gH2AX.cpipe**.

2.3.4. Drag-and-drop the folder containing the acquired images of γ H2A.X foci to the **File list** window in the **Input modules/Images** section for analysis (**Figure 5A**). Then, follow the instructions as shown in **Figure 5A-L**.

2.3.5. Set the following parameters for the images:

2.3.5.1. Drag the desired image for analysis onto the **File list**. Under **Input modules**, select **Images** (see **Figure 5A** for module settings). In **Input modules**, select **Metadata** (see **Figure 5B** for module settings). In **Input modules**, select **NamesAndTypes** (see **Figure 5C** for module settings).

2.3.5.2. For **Groups**, select **no**. In **Analysis modules**, select **ColorToGray** (see **Figure 5D** for module settings).

265
266 2.3.6. In **Analysis modules**, select **Smooth** (see **Figure 5E** for module settings).

267
268 NOTE: This value may need to be optimized, depending on the image resolution.

269
270 2.3.7. In **Analysis modules**, select **IdentifyPrimaryObjects** (see **Figure 5F** for module settings).

271
272 NOTE: Optimize these values to make sure the whole nucleus is selected. After this step, the
273 computer may lag.

274
275 2.3.8. In **Analysis modules**, select **Smooth** (see **Figure 5G** for module settings).

276
277 NOTE: This value may need to be optimized, depending on the image resolution.

278
279 2.3.9. In **Analysis modules**, select **EnhanceOrSuppressFeatures** (see **Figure 5H** for module
280 settings).

281
282 2.3.10. In **Analysis modules**, select **IdentifyPrimaryObjects** (see **Figure 5I** for module settings).

283
284 NOTE: Optimize these values to make sure the punctae are selected. After this step, the computer
285 may lag again.

286
287 2.3.10.1. In **Analysis modules**, select **RelateObjects** (see **Figure 5J** for module settings). In
288 **Analysis modules**, select **ClassifyObjects** (see **Figure 5K** for module settings). In **Analysis**
289 **modules**, select **ExportToSpreadsheet** (see **Figure 5L** for module settings).

290
291 2.3.10.2. Click **Analyze Images** at the bottom left panel to perform image analysis. At the
292 successful completion of the analysis, several images are generated (**Figure 6A-F**).

293
294 NOTE: Users should save these images for future reference.

295
296 2.3.10.3. Note the .csv file containing the quantitative data for further analysis that is generated
297 and saved in the appropriate location on the computer. In the spreadsheet called **MyExpt_Image**,
298 columns B and D will have the number of nuclei that have up to five and more punctae,
299 respectively. Add columns B and D to get the total number of nuclei.

300
301 2.3.11. Repeat step 2.3.3 - 2.3.8 for all images (change the **MyExpt_** filename before every
302 analysis). Plots can be made for assessing DNA integrity, as shown in **Figure 4C**.

303 304 REPRESENTATIVE RESULTS:

305 Human induced pluripotent stem cells were cultured, and the DNA damage and the tail moment,
306 which were used as a measure of DNA integrity, were analyzed by comet assay. iPS cells were
307 embedded in low-melting-point agarose and placed on a glass slide. The cells were, then, treated
308 with lysis buffer, followed by an alkaline solution, to obtain supercoiled DNA. Nucleoids were

electrophoresed and comets were visualized by DNA dye (**Figure 1A-D**). The comets were, then, analyzed with ImageJ, using the comet assay plugin (**Figure 2A-C**).

Human iPS cells were treated with Doxo to induce DNA damage and to be used as a positive control. Representative micrographs of comets from Doxo-treated and nontreated iPS cells are shown in **Figure 3A**. A basal amount of DNA damage was found in iPS cells, expressed as a fraction of DNA damage and tail moment. However, the Doxo treatment increased the DNA damage in iPS cells as expected (**Figure 3B,C**). This shows that the comet assay can be used to assess DNA integrity not only in somatic cells^{18,19} but also in pluripotent stem cells²¹.

Freshly differentiated iPS cardiomyocytes (iPS-CMs), iPS-CMs cultured for 6 months (prolonged culture [PC]), and iPS-CMs treated with Doxo were subjected to γ H2A.X immunolabeling. Representative micrographs of γ H2A.X immunolabelling are shown in **Figure 4A** (lower-magnification) and **Figure 4B** (higher-magnification). The number of γ H2A.X foci (DDR foci) (punctae) in each nucleus are quantified, using CellProfiler with custom pipeline modules (**Figure 5A-L**). The percentage of cells that are positive for γ H2A.X are classified into nuclei with zero to five punctae and nuclei with more than 10 punctae. In the control iPS-CM, more than 90% of the cells had less than five DDR foci per nuclei, and a total of less than 10% of the cells had more than six DDR foci per nuclei (**Figure 4C**, control [Ctrl]). iPS-CMs cultured for 6 months had less than 90% cells with less than five DDR foci per nuclei, and a total of more than 13% of the cells had more than six DDR foci per nuclei (**Figure 4C**, PC), whereas the Doxo-treated iPS-CM showed less than 80% of the cells with less than five DDR foci per nuclei, and a total of about 24% of the cells had more than six DDR foci per nuclei (**Figure 4C**, Doxo). This data clearly shows that prolonged cell culture and Doxo treatment induce significant DNA damage in iPS-CMs and are not suitable for cell transplantation.

FIGURE LEGENDS:

Figure 1: Schematic of the comet assay. (A) Mix the cell suspension with low-melting-point agarose and (B) place it on a glass slide. (C) Treat it with cell lysis buffer, followed by an alkaline solution, to get nucleoids containing supercoiled DNA. (D) Electrophorese and stain the DNA using SYBR green DNA dye. (E) Schematic of intact (left) and damaged DNA (right, comet shape). (F) Formula to calculate a fraction of the DNA damage and tail moment.

Figure 2: DNA damage and tail moment quantification by ImageJ. (A - C) Screenshots of ImageJ, with the comet analysis plugin showing a selection of the comet head and tail.

Figure 3: Doxorubicin induces DNA damage in human iPS cells. (A) DNA damage in doxorubicin-treated (Doxo) and nontreated (control) iPS cells, analyzed using the comet assay. (B) Fraction of DNA damage ($n = 3$) and (C) tail moment ($n = 63$ comets) quantified using the comet assay. Treatment with doxorubicin, a DNA-intercalating agent, significantly increased the fraction of DNA damage and tail moment in iPS cells. Data are means \pm SEM. $*P < 0.05$, Student's unpaired t -test.

Figure 4: DNA damage response in iPS-derived cardiomyocytes. (A) DNA damage response marker γ H2A.X identified by immunofluorescence in doxorubicin-treated (Doxo) and nontreated (control) iPS-cardiomyocytes as well as prolonged culture iPS-cardiomyocytes (PC). (B) Higher magnification of γ H2A.X (green punctae) labeling at the sites of DNA damage in iPS-CMs. (C) Quantification of DDR foci, analyzed using CellProfiler with custom pipeline modules. Data are means \pm SD; $n = 3$ to 4. * $P < 0.05$, Student's unpaired t -test.

Figure 5: Automated DNA damage response analysis by CellProfiler. (A - L) Screenshots of CellProfiler with specified settings for importing the images, and the automated identification and quantification of γ H2A.X punctae in iPS-CMs.

Figure 6: Automated DNA damage response analysis by CellProfiler. (A - F) Data images generated by CellProfiler at the completion of the image analysis.

DISCUSSION:

DNA integrity portrays cell integrity. Cells with damaged DNA are frequently in stress and eventually lose their integrity. The integrity of stem and stem-cell-derived cells that are being propagated for the purpose of transplantation is principal for the cells to perform their desired function. Transplanting cells with damaged DNA would result in a poor engraftment rate and performance of the cell^{8,20}. Therefore, examining the DNA integrity prior to cell transplantation is a necessary quality control protocol. Here we describe two cost-effective approaches, namely the comet assay and γ H2A.X immunofluorescence labeling, to assess the DNA damage and quality of stem and stem-cell-derived cells.

A major cause of cellular aging is thought to be the accumulation of DNA damage in cells. Using the comet assay, Al-Baker *et al.* analyzed the DNA damage in young and senescent human dermal fibroblasts²². Previously, we have shown that transplanting DNA damage-free cardiac progenitor cells isolated from a p53 transgenic mouse increased the rate of engraftment in the host organ⁸. Recently, we have shown the role of the p53 transactivation domain in DNA damage repair mechanisms in human iPS cells²¹. In both studies, we have employed both the comet assay and γ H2A.X immunofluorescence labeling methodologies to assess the DNA damage in stem cells. Both these methods are cost-effective and can be performed with basic lab equipment. An annoying critical problem that we often experienced is agarose solidifying in the pipette and tubes. We overcome this issue by prewarming all the tubes and tips prior to pipetting agarose. While the comet assay takes up to 2 days to complete, the optimized γ H2A.X immunofluorescence labeling procedure can be completed in under 4 h.

Human iPS cell cultures with more than 10% DNA damage, measured by the comet assay, did not efficiently differentiate into cardiomyocytes (data not shown) *in vitro*. The comet assay is sensitive and dynamic in assessing DNA damage in stem cells. However, DNA integrity assessments in certain cells, such as iPS-derived cardiomyocytes, are cumbersome by comet assay due to the nature of the cells. The cardiomyocytes are enriched with troponin, sarcomeric proteins, and the secreted extracellular matrix proteins. Denaturing these complex structures to make supercoiled DNA and its reproducibility are questionable. Most importantly, 25% to 40% of

human cardiomyocytes are binucleated²⁵, and these percentages vary in iPS-derived cardiomyocytes. Since the cell wall is disrupted in the comet assay, the precise assessment of the percentage of DNA-damaged cells is impossible. Therefore, in the case of iPS-CMs, the γ H2A.X immunofluorescence labeling procedure to assess DNA damage is a simplistic alternative for the comet assay.

Based on these results and those from previous publications by our group^{8,20,21}, we suggest that, if there is more than 10% DNA damage, assessed by the comet assay, or less than 90% of the cells have zero to five DDR foci, then the culture should be disqualified for cell transplantation.

ACKNOWLEDGMENTS:

This work was supported in part by National Heart, Lung, and Blood Institute Grants RO1-HL-99507, HL-114120, HL-131017, HL138023, and UO1-HL-134764 (to J. Zhang) and by American Heart Association Scientific Development Grant 17SDG33670677 (to R. Kannappan).


DISCLOSURES:

The authors have nothing to disclose.


REFERENCES:

1. Bolli, R. *et al.* Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. *The Lancet*. **378** (9806), 1847-1857 (2011).
2. Makkar, R. R. *et al.* Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial. *The Lancet*. **379** (9819), 895-904 (2012).
3. Tomita, Y. *et al.* Cardiac neural crest cells contribute to the dormant multipotent stem cell in the mammalian heart. *Journal of Cell Biology*. **170** (7), 1135-1146 (2005).
4. Oyama, T. *et al.* Cardiac side population cells have a potential to migrate and differentiate into cardiomyocytes *in vitro* and *in vivo*. *Journal of Cell Biology*. **176** (3), 329-341 (2007).
5. Fischer, K. M. *et al.* Enhancement of myocardial regeneration through genetic engineering of cardiac progenitor cells expressing Pim-1 kinase. *Circulation*. **120** (21), 2077-2087 (2009).
6. Cottage, C. T. *et al.* Cardiac progenitor cell cycling stimulated by pim-1 kinase. *Circulation Research*. **106** (5), 891-901 (2010).
7. Angert, D. *et al.* Repair of the injured adult heart involves new myocytes potentially derived from resident cardiac stem cells. *Circulation Research*. **108** (10), 1226-1237 (2011).
8. Kannappan, R. *et al.* p53 Modulates the Fate of Cardiac Progenitor Cells *Ex vivo* and in the Diabetic Heart *In vivo*. *EBioMedicine*. **16**, 224-237 (2017).
9. Hatzistergos, K. E. *et al.* Bone marrow mesenchymal stem cells stimulate cardiac stem cell proliferation and differentiation. *Circulation Research*. **107** (7), 913-922 (2010).
10. Okita, K., Yamanaka, S. Induced pluripotent stem cells: opportunities and challenges. *Philosophical Transactions of the Royal Society B Biological Sciences*. **366** (1575), 2198-2207 (2011).
11. Zhang, J. *et al.* Functional cardiomyocytes derived from human induced pluripotent stem cells. *Circulation Research*. **104** (4), e30-41 (2009).


12. Ye, L. *et al.* Cardiac repair in a porcine model of acute myocardial infarction with human induced pluripotent stem cell-derived cardiovascular cells. *Cell Stem Cell*. **15** (6), 750-761 (2014).
13. Zhang, L. *et al.* Derivation and high engraftment of patient-specific cardiomyocyte sheet using induced pluripotent stem cells generated from adult cardiac fibroblast. *Circulation: Heart Failure*. **8** (1), 156-166 (2015).
14. Hirakawa, K., Midorikawa, K., Oikawa, S., Kawanishi, S. Carcinogenic semicarbazide induces sequence-specific DNA damage through the generation of reactive oxygen species and the derived organic radicals. *Mutation Research*. **536** (1-2), 91-101 (2003).
15. Martinez, G. R. *et al.* Oxidative and alkylating damage in DNA. *Mutation Research*. **544** (2-3), 115-127 (2003).
16. Valko, M., Rhodes, C. J., Moncol, J., Izakovic, M., Mazur, M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. *Chemico-Biological Interactions*. **160** (1), 1-40 (2006).
17. Wiseman, H., Halliwell, B. Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer. *Biochemical Journal*. **313** (Pt 1), 17-29 (1996).
18. Ostling, O., Johanson, K. J. Microelectrophoretic study of radiation-induced DNA damages in individual mammalian cells. *Biochemical and Biophysical Research Communications*. **123** (1), 291-298 (1984).
19. Singh, N. P., McCoy, M. T., Tice, R. R., Schneider, E. L. A simple technique for quantitation of low levels of DNA damage in individual cells. *Experimental Cell Research*. **175** (1), 184-191 (1988).
20. Goichberg, P. *et al.* Age-associated defects in EphA2 signaling impair the migration of human cardiac progenitor cells. *Circulation*. **128** (20), 2211-2223 (2013).
21. Kannappan, R., Mattapally, S., Wagle, P. A., Zhang, J. Transactivation domain of p53 regulates DNA repair and integrity in human iPS cells. *American Journal of Physiology-Heart and Circulatory Physiology*. 10.1152/ajpheart.00160.2018 (2018).
22. Al-Baker, E. A., Oshin, M., Hutchison, C. J., Kill, I. R. Analysis of UV-induced damage and repair in young and senescent human dermal fibroblasts using the comet assay. *Mechanisms of Ageing and Development*. **126** (6-7), 664-672 (2005).
23. Azqueta, A., Gutzkow, K. B., Brunborg, G., Collins, A. R. Towards a more reliable comet assay: optimising agarose concentration, unwinding time and electrophoresis conditions. *Mutation Research*. **724** (1-2), 41-45 (2011).
24. Carpenter, A. E. *et al.* CellProfiler: image analysis software for identifying and quantifying cell phenotypes. *Genome Biology*. **7** (10), R100 (2006).
25. Paradis, A. N., Gay, M. S., Zhang, L. Binucleation of cardiomyocytes: the transition from a proliferative to a terminally differentiated state. *Drug Discovery Today*. **19** (5), 602-609 (2014).




A






B




C









A




B




C




D




E




F




G




H




I




J









K



L



A**ColortoGray****B****Smooth****C****IdentifyPrimaryObjects****D****EnhanceOrSuppress****E****IdentifyPrimaryObjects****F****RelateObjects**

Name of Material/Equipment	Company
0.25% Trypsin	Corning
8-well chamber slide	Millicell
Accutase	Stemcell Technologies
Alexa Fluor 488 AffiniPure	Jackson Immuno
Donkey Anti-Rabbit IgG	Research Laboratories
Bovine Serum Albumin	Sigma-Aldrich
Cy3 AffiniPure Donkey Anti-Rabbit IgG	Jackson Immuno
	Research Laboratories
DAPI	Sigma-Aldrich
Gibco B-27 Supplement, Serum Free,	Gibco
Matrigel growth factor reduced	Corning
mTeSR1	Stemcell Technologies
PhalloidinA488	Life Technology
Phospho-Histone H2A.X (Ser139) Antibody	Cell Signaling Technology
RPMI	Gibco
SYBR Green I nucleic acid gel stain	Sigma-Aldrich
Triton X-100	Fisher scientific
UltraPure Low melting Point Agarose	Invitrogen
Vectashield	Vector Laboratories

Catalog Number	Notes
25200056	
PEZGS0816	
7920	Cell detachment solution
711-545-152	
(RRID: AB_2313584)	
A7906	
711-165-152	
(RRID:AB_2307443)	
D9564	
17504-044	
354230	
85850	
A12379	
2577 (RRID: AB_2118010)	
11875-093	
S9430	
BP151-100	
16520050	
H-1000	Antifade



1 Alewife Center #200
Cambridge, MA 02140
tel. 617.945.9051
www.jove.com

ARTICLE AND VIDEO LICENSE AGREEMENT

Title of Article:

Assessing Stem Cell DNA Integrity for Cardiac Cell Therapy

Author(s):

Jessica M Miller, Nikhil Mardhekar, Vasanthi Rajasekaran, Jianyi Zhang, Ramaswamy Kannappan

Item 1 (check one box): The Author elects to have the Materials be made available (as described at

<http://www.jove.com/author>) via: ☒ Standard Access ☐ Open Access

Item 2 (check one box):



The Author is NOT a United States government employee.



The Author is a United States government employee and the Materials were prepared in the course of his or her duties as a United States government employee.



The Author is a United States government employee but the Materials were NOT prepared in the course of his or her duties as a United States government employee.

ARTICLE AND VIDEO LICENSE AGREEMENT

1. Defined Terms. As used in this Article and Video License Agreement, the following terms shall have the following meanings: “**Agreement**” means this Article and Video License Agreement; “**Article**” means the article specified on the last page of this Agreement, including any associated materials such as texts, figures, tables, artwork, abstracts, or summaries contained therein; “**Author**” means the author who is a signatory to this Agreement; “**Collective Work**” means a work, such as a periodical issue, anthology or encyclopedia, in which the Materials in their entirety in unmodified form, along with a number of other contributions, constituting separate and independent works in themselves, are assembled into a collective whole; “**CRC License**” means the Creative Commons Attribution-Non Commercial-No Derivs 3.0 Unported Agreement, the terms and conditions of which can be found at: <http://creativecommons.org/licenses/by-nc-nd/3.0/legalcode>; “**Derivative Work**” means a work based upon the Materials or upon the Materials and other pre-existing works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment, condensation, or any other form in which the Materials may be recast, transformed, or adapted; “**Institution**” means the institution, listed on the last page of this Agreement, by which the Author was employed at the time of the creation of the Materials; “**JoVE**” means MyJoVE Corporation, a Massachusetts corporation and the publisher of *The Journal of Visualized Experiments*; “**Materials**” means the Article and / or the Video; “**Parties**” means the Author and JoVE; “**Video**” means any video(s) made by the Author, alone or in conjunction with any other parties, or by JoVE or its affiliates or agents, individually or in collaboration with the Author or any other parties, incorporating all or any portion of the Article, and in which the Author may or may not appear.

2. Background. The Author, who is the author of the Article, in order to ensure the dissemination and protection of the Article, desires to have the JoVE publish the Article and create and transmit videos based on the Article. In furtherance of such goals, the Parties desire to memorialize in this Agreement the respective rights of each Party in and to the Article and the Video.

3. Grant of Rights in Article. In consideration of JoVE agreeing to publish the Article, the Author hereby grants to JoVE, subject to **Sections 4** and **7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Article in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Article into other languages, create adaptations, summaries or extracts of the Article or other Derivative Works (including, without limitation, the Video) or Collective Works based on all or any portion of the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. If the “Open Access” box has been checked in **Item 1** above, JoVE and the Author hereby grant to the public all such rights in the Article as provided in, but subject to all limitations and requirements set forth in, the CRC License.

ARTICLE AND VIDEO LICENSE AGREEMENT

4. Retention of Rights in Article. Notwithstanding the exclusive license granted to JoVE in **Section 3** above, the Author shall, with respect to the Article, retain the non-exclusive right to use all or part of the Article for the non-commercial purpose of giving lectures, presentations or teaching classes, and to post a copy of the Article on the Institution's website or the Author's personal website, in each case provided that a link to the Article on the JoVE website is provided and notice of JoVE's copyright in the Article is included. All non-copyright intellectual property rights in and to the Article, such as patent rights, shall remain with the Author.

5. Grant of Rights in Video – Standard Access. This **Section 5** applies if the "Standard Access" box has been checked in **Item 1** above or if no box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby acknowledges and agrees that, Subject to **Section 7** below, JoVE is and shall be the sole and exclusive owner of all rights of any nature, including, without limitation, all copyrights, in and to the Video. To the extent that, by law, the Author is deemed, now or at any time in the future, to have any rights of any nature in or to the Video, the Author hereby disclaims all such rights and transfers all such rights to JoVE.

6. Grant of Rights in Video – Open Access. This **Section 6** applies only if the "Open Access" box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby grants to JoVE, subject to **Section 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Video in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Video into other languages, create adaptations, summaries or extracts of the Video or other Derivative Works or Collective Works based on all or any portion of the Video and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. For any Video to which this Section 6 is applicable, JoVE and the Author hereby grant to the public all such rights in the Video as provided in, but subject to all limitations and requirements set forth in, the CRC License.

7. Government Employees. If the Author is a United States government employee and the Article was prepared in the course of his or her duties as a United States government employee, as indicated in **Item 2** above, and any of the licenses or grants granted by the Author hereunder exceed the scope of the 17 U.S.C. 403, then the rights granted hereunder shall be limited to the maximum rights permitted under such

statute. In such case, all provisions contained herein that are not in conflict with such statute shall remain in full force and effect, and all provisions contained herein that do so conflict shall be deemed to be amended so as to provide to JoVE the maximum rights permissible within such statute.

8. Likeness, Privacy, Personality. The Author hereby grants JoVE the right to use the Author's name, voice, likeness, picture, photograph, image, biography and performance in any way, commercial or otherwise, in connection with the Materials and the sale, promotion and distribution thereof. The Author hereby waives any and all rights he or she may have, relating to his or her appearance in the Video or otherwise relating to the Materials, under all applicable privacy, likeness, personality or similar laws.

9. Author Warranties. The Author represents and warrants that the Article is original, that it has not been published, that the copyright interest is owned by the Author (or, if more than one author is listed at the beginning of this Agreement, by such authors collectively) and has not been assigned, licensed, or otherwise transferred to any other party. The Author represents and warrants that the author(s) listed at the top of this Agreement are the only authors of the Materials. If more than one author is listed at the top of this Agreement and if any such author has not entered into a separate Article and Video License Agreement with JoVE relating to the Materials, the Author represents and warrants that the Author has been authorized by each of the other such authors to execute this Agreement on his or her behalf and to bind him or her with respect to the terms of this Agreement as if each of them had been a party hereto as an Author. The Author warrants that the use, reproduction, distribution, public or private performance or display, and/or modification of all or any portion of the Materials does not and will not violate, infringe and/or misappropriate the patent, trademark, intellectual property or other rights of any third party. The Author represents and warrants that it has and will continue to comply with all government, institutional and other regulations, including, without limitation all institutional, laboratory, hospital, ethical, human and animal treatment, privacy, and all other rules, regulations, laws, procedures or guidelines, applicable to the Materials, and that all research involving human and animal subjects has been approved by the Author's relevant institutional review board.

10. JoVE Discretion. If the Author requests the assistance of JoVE in producing the Video in the Author's facility, the Author shall ensure that the presence of JoVE employees, agents or independent contractors is in accordance with the relevant regulations of the Author's institution. If more than one author is listed at the beginning of this Agreement, JoVE may, in its sole discretion, elect not take any action with respect to the Article until such time as it has received complete, executed Article and Video License Agreements from each such author. JoVE reserves the right, in its absolute and sole discretion and without giving any reason therefore, to accept or decline any work submitted to JoVE. JoVE and its employees, agents and independent contractors shall have

ARTICLE AND VIDEO LICENSE AGREEMENT

full, unfettered access to the facilities of the Author or of the Author's institution as necessary to make the Video, whether actually published or not. JoVE has sole discretion as to the method of making and publishing the Materials, including, without limitation, to all decisions regarding editing, lighting, filming, timing of publication, if any, length, quality, content and the like.

11. **Indemnification.** The Author agrees to indemnify JoVE and/or its successors and assigns from and against any and all claims, costs, and expenses, including attorney's fees, arising out of any breach of any warranty or other representations contained herein. The Author further agrees to indemnify and hold harmless JoVE from and against any and all claims, costs, and expenses, including attorney's fees, resulting from the breach by the Author of any representation or warranty contained herein or from allegations or instances of violation of intellectual property rights, damage to the Author's or the Author's institution's facilities, fraud, libel, defamation, research, equipment, experiments, property damage, personal injury, violations of institutional, laboratory, hospital, ethical, human and animal treatment, privacy or other rules, regulations, laws, procedures or guidelines, liabilities and other losses or damages related in any way to the submission of work to JoVE, making of videos by JoVE, or publication in JoVE or elsewhere by JoVE. The Author shall be responsible for, and shall hold JoVE harmless from, damages caused by lack of sterilization, lack of cleanliness or by contamination due to the making of a video by JoVE its employees, agents or independent contractors. All sterilization, cleanliness or decontamination procedures shall be solely the responsibility of the Author and shall be undertaken at the Author's


expense. All indemnifications provided herein shall include JoVE's attorney's fees and costs related to said losses or damages. Such indemnification and holding harmless shall include such losses or damages incurred by, or in connection with, acts or omissions of JoVE, its employees, agents or independent contractors.

12. **Fees.** To cover the cost incurred for publication, JoVE must receive payment before production and publication the Materials. Payment is due in 21 days of invoice. Should the Materials not be published due to an editorial or production decision, these funds will be returned to the Author. Withdrawal by the Author of any submitted Materials after final peer review approval will result in a US\$1,200 fee to cover pre-production expenses incurred by JoVE. If payment is not received by the completion of filming, production and publication of the Materials will be suspended until payment is received.

13. **Transfer, Governing Law.** This Agreement may be assigned by JoVE and shall inure to the benefits of any of JoVE's successors and assignees. This Agreement shall be governed and construed by the internal laws of the Commonwealth of Massachusetts without giving effect to any conflict of law provision thereunder. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

A signed copy of this document must be sent with all new submissions. Only one Agreement required per submission.

CORRESPONDING AUTHOR:

Name:	Ramaswamy Kannappan	
Department:	Biomedical Engineering	
Institution:	University of Alabama at Birmingham	
Article Title:	Assessing Stem Cell DNA Integrity for Cardiac Cell Therapy	
Signature:		Date: 08/20/2018

Please submit a signed and dated copy of this license by one of the following three methods:

- 1) Upload a scanned copy of the document as a pdf on the JoVE submission site;
- 2) Fax the document to +1.866.381.2236;
- 3) Mail the document to JoVE / Attn: JoVE Editorial / 1 Alewife Center #200 / Cambridge, MA 02139

For questions, please email submissions@jove.com or call +1.617.945.9051

Response to comments

Manuscript # JoVE58971

“Assessing Stem Cell DNA Integrity for Cardiac Cell Therapy”

Editorial comments:

Comment: When text is formatted per JoVE guidelines (12 pt Calibri font, all text at the left margin, spaces between numbered steps/substeps; see attached manuscript), the highlighted protocol is ~6.5 pages; our limit (for filming and video length purposes) is 2.75 pages. Please consolidate shorter substeps and otherwise reduce the highlighted portion of the protocol.

Response: The highlighted protocol is now corrected to 2.75 pages.

Comment: Please remove ‘Figure 1/2/etc’ from the Figures themselves.

Response: Figure 1/2/etc’ were removed from the Figures

Comment: Please number the Figures in the order they appear in the text; currently, Figures 5 and 6 appear before Figures 2-4.

Response:

Line 80 - Figure 1

Line 124 - Figure 2

Line 125 - Figure 3

Line 171 - Figure 4

Line 181 - Figure 5

Line 204 - Figure 6

These are the orders figures appear initially. After line 204, figures are cross referenced.

Comment: Figures 3 and 4: What statistical test was used to produce these P-values?


Response: Student’s unpaired Two-tailed t test was used in all cases. Figure 4: t-test was performed between samples as indicated in the figure.

Comment: Figure 3C: Unless some points are overlapping, the presented S.D. for the Doxo group looks rather small.

Response: Thanks for pointing out this typo error. It is SEM, not S.D.

Comment: Please consolidate the 2 parts of Figure 5 into one Figure.

Response: 2 parts of Figure 5 are now consolidated into one page. After consolidating into a one page figure, the authors feel the images are too small to read.



Click here to access/download
Supplemental Coding Files
punctae_gH2AX.cppipe

